Related Experiment Video

Updated: Jun 17, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

p38 in chronic myelogenous leukemia: a target and a possible biomarker

Suman Kambhampati1

  • 1Cancer Research Unit, VA Medical Center, Kansas City, Missouri 64128, USA. skambhampati@kumc.edu

Leukemia & Lymphoma
|December 17, 2009
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Converging Pathways in Cancer Biology: How Do the Microbiome, Angiogenesis, Senescence, Fibroblast Plasticity, and Immunotherapy Intertwine?

Cancers·2026

Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells.

Molecular therapy. Oncology·2025

Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells.

Research square·2025

Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

Clinical hematology international·2024

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Blood·2024

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.

Future oncology (London, England)·2023

Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

Leukemia & lymphoma·2026

The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.

Leukemia & lymphoma·2026

Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis.

Leukemia & lymphoma·2026

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Leukemia & lymphoma·2026

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Leukemia & lymphoma·2026

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Leukemia & lymphoma·2026

COVID-19 Vaccination and Risk of Post-COVID-19 Cardiovascular Disease: A Population-Based Cohort and Target Trial Emulation Study.

European heart journal. Quality of care & clinical outcomes·2026

Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.

Annals of medicine·2026

Prophylactic tramadol for oxaliplatin-induced peripheral vascular pain: a single-arm retrospective study.

Anti-cancer drugs·2026

Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.

JAMA internal medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us